Enoxaparin sodium
- Generic Name
- Enoxaparin sodium
- Brand Names
- Lovenox, Inhixa
- Drug Type
- Small Molecule
- CAS Number
- 9005-49-6
- Unique Ingredient Identifier
- E47C0NF7LV
- Background
Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated heparin, without increasing the risk of serious bleeding.
- Indication
Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.
Enoxaparin is also indicated in the prophylaxis of DVT in abdominal surgery, hip replacement, knee replacement, or medical patients with severely restricted mobility during acute illness. Additionally, enoxaparin is indicated for the inpatient treatment of DVT with or without pulmonary embolism and the treatment of outpatient DVT without pulmonary embolism.
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina
- Associated Therapies
- Percutaneous Coronary Intervention (PCI)
Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
- Conditions
- PreventionVenous Thromboembolism
- Interventions
- First Posted Date
- 2006-05-31
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2457
- Registration Number
- NCT00332020
Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin
- Conditions
- Venous Thromboembolism
- Interventions
- First Posted Date
- 2006-05-25
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 4541
- Registration Number
- NCT00329628
LV Thrombus Pilot Study for Comparing Enoxaparin Vs. Warfarin
- Conditions
- Coronary Artery DiseaseAcute Myocardial Infarction
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2006-05-03
- Lead Sponsor
- William Beaumont Hospitals
- Target Recruit Count
- 60
- Registration Number
- NCT00321009
- Locations
- 🇺🇸
William Beaumont Hospital, Royal Oak, Michigan, United States
🇺🇸Doylestown Hospital, Doylestown, Pennsylvania, United States
🇺🇸LaBauer Cardiovascular Research Foundation, Greensboro, North Carolina, United States
Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery
- Conditions
- Venous Thrombosis
- First Posted Date
- 2006-03-23
- Last Posted Date
- 2007-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1225
- Registration Number
- NCT00306254
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
ABRIDGE: Low Molecular Weight Heparin in Bridging Patients After Mechanical Valve Replacement
- Conditions
- Warfarin TherapyMechanical Valve Replacement
- First Posted Date
- 2006-03-02
- Last Posted Date
- 2007-11-09
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 100
- Registration Number
- NCT00298285
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
Assessment of Cardioversion Using Transesophageal Echocardiography II (ACUTE II)
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2006-02-09
- Last Posted Date
- 2007-01-31
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 200
- Registration Number
- NCT00289042
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
Enoxaparin in Acute Venous Thromboembolic Disease
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2010-02-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 251
- Registration Number
- NCT00265993
- Locations
- 🇹🇷
Sanofi-Aventis Administrative Office, Istanbul, Turkey
Patients Preference With Self-Injection: The PRISM Study
- Conditions
- Bruises
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2009-03-10
- Lead Sponsor
- Hamilton Health Sciences Corporation
- Target Recruit Count
- 100
- Registration Number
- NCT00253396
- Locations
- 🇨🇦
St. Joseph's Healthcare, Hamilton, Ontario, Canada
The Effect of Enoxaparin Sodium on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- Melbourne Health
- Target Recruit Count
- 35
- Registration Number
- NCT00232271
- Locations
- 🇦🇺
Royal Melbourne hospital, Melbourne, Victoria, Australia
Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa (Activated): Phase II Exploratory Study
- Conditions
- Submassive Pulmonary Embolism
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2009-06-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 47
- Registration Number
- NCT00191724
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mannheim, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.